Simple multicystic dysplastic kidney disease: End points for subspecialty follow-up

Adam Weinstein, T. Rob Goodman, Sandra Iragorri

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Simple multicystic dysplastic kidney (MCDK) disease, defined as unilateral MCDK without other genitourinary tract involvement, portends an excellent prognosis. Nevertheless, its long-term management remains undefined. This study aims to provide subspecialty discharge recommendations for these patients. We identified eighty patients with simple MCDK disease by renal ultrasound between 1996 and 2006. Their charts were reviewed for growth of the contralateral kidney, involution of the MCDK, and incidence of complications, specifically hypertension, chronic renal insufficiency (CRI), urinary tract infection (UTI), and malignancy. Mean follow-up was 5 years. At approximately 1 year, 59% of unaffected kidneys were hypertrophied (≥95th percentile for age/ height) and 100% were >50th percentile. With continued follow-up, 80.3% of unaffected kidneys were hypertrophied. Likewise, at 1 year, 71.2% of MCDKs assessed were either involuting or had disappeared; on further follow-up, this increased to 89.6%. No patient had hypertension, CRI, or malignancy. Four patients (5%) developed nonrecurrent UTIs, none leading to renal scarring or growth impairment. These data suggest that subspecialty follow-up may be discontinued once contralateral hypertrophy and ipsilateral involution occur, assuming that the patient has not experienced hypertension, CRI, or UTI. These criteria are often met by 1 year of age, which would preclude repeated visits, uncomfortable investigations, and unnecessary costs.

Original languageEnglish (US)
Pages (from-to)111-116
Number of pages6
JournalPediatric Nephrology
Volume23
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Multicystic Dysplastic Kidney
Kidney Diseases
Kidney
Chronic Renal Insufficiency
Hypertension
Urinary Tract Infections
Patient Discharge
Growth
Hypertrophy
Cicatrix
Neoplasms
Costs and Cost Analysis
Incidence

Keywords

  • MCDK involution
  • Multicystic dysplastic kidney (MCDK)
  • Prognosis
  • Simple MCDK
  • Single kidney compensatory hypertrophy
  • Treatment
  • Unilateral cystic kidney

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Simple multicystic dysplastic kidney disease : End points for subspecialty follow-up. / Weinstein, Adam; Goodman, T. Rob; Iragorri, Sandra.

In: Pediatric Nephrology, Vol. 23, No. 1, 01.2008, p. 111-116.

Research output: Contribution to journalArticle

@article{37928e683e6542a197c7c5b71fe7fb68,
title = "Simple multicystic dysplastic kidney disease: End points for subspecialty follow-up",
abstract = "Simple multicystic dysplastic kidney (MCDK) disease, defined as unilateral MCDK without other genitourinary tract involvement, portends an excellent prognosis. Nevertheless, its long-term management remains undefined. This study aims to provide subspecialty discharge recommendations for these patients. We identified eighty patients with simple MCDK disease by renal ultrasound between 1996 and 2006. Their charts were reviewed for growth of the contralateral kidney, involution of the MCDK, and incidence of complications, specifically hypertension, chronic renal insufficiency (CRI), urinary tract infection (UTI), and malignancy. Mean follow-up was 5 years. At approximately 1 year, 59{\%} of unaffected kidneys were hypertrophied (≥95th percentile for age/ height) and 100{\%} were >50th percentile. With continued follow-up, 80.3{\%} of unaffected kidneys were hypertrophied. Likewise, at 1 year, 71.2{\%} of MCDKs assessed were either involuting or had disappeared; on further follow-up, this increased to 89.6{\%}. No patient had hypertension, CRI, or malignancy. Four patients (5{\%}) developed nonrecurrent UTIs, none leading to renal scarring or growth impairment. These data suggest that subspecialty follow-up may be discontinued once contralateral hypertrophy and ipsilateral involution occur, assuming that the patient has not experienced hypertension, CRI, or UTI. These criteria are often met by 1 year of age, which would preclude repeated visits, uncomfortable investigations, and unnecessary costs.",
keywords = "MCDK involution, Multicystic dysplastic kidney (MCDK), Prognosis, Simple MCDK, Single kidney compensatory hypertrophy, Treatment, Unilateral cystic kidney",
author = "Adam Weinstein and Goodman, {T. Rob} and Sandra Iragorri",
year = "2008",
month = "1",
doi = "10.1007/s00467-007-0635-7",
language = "English (US)",
volume = "23",
pages = "111--116",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Simple multicystic dysplastic kidney disease

T2 - End points for subspecialty follow-up

AU - Weinstein, Adam

AU - Goodman, T. Rob

AU - Iragorri, Sandra

PY - 2008/1

Y1 - 2008/1

N2 - Simple multicystic dysplastic kidney (MCDK) disease, defined as unilateral MCDK without other genitourinary tract involvement, portends an excellent prognosis. Nevertheless, its long-term management remains undefined. This study aims to provide subspecialty discharge recommendations for these patients. We identified eighty patients with simple MCDK disease by renal ultrasound between 1996 and 2006. Their charts were reviewed for growth of the contralateral kidney, involution of the MCDK, and incidence of complications, specifically hypertension, chronic renal insufficiency (CRI), urinary tract infection (UTI), and malignancy. Mean follow-up was 5 years. At approximately 1 year, 59% of unaffected kidneys were hypertrophied (≥95th percentile for age/ height) and 100% were >50th percentile. With continued follow-up, 80.3% of unaffected kidneys were hypertrophied. Likewise, at 1 year, 71.2% of MCDKs assessed were either involuting or had disappeared; on further follow-up, this increased to 89.6%. No patient had hypertension, CRI, or malignancy. Four patients (5%) developed nonrecurrent UTIs, none leading to renal scarring or growth impairment. These data suggest that subspecialty follow-up may be discontinued once contralateral hypertrophy and ipsilateral involution occur, assuming that the patient has not experienced hypertension, CRI, or UTI. These criteria are often met by 1 year of age, which would preclude repeated visits, uncomfortable investigations, and unnecessary costs.

AB - Simple multicystic dysplastic kidney (MCDK) disease, defined as unilateral MCDK without other genitourinary tract involvement, portends an excellent prognosis. Nevertheless, its long-term management remains undefined. This study aims to provide subspecialty discharge recommendations for these patients. We identified eighty patients with simple MCDK disease by renal ultrasound between 1996 and 2006. Their charts were reviewed for growth of the contralateral kidney, involution of the MCDK, and incidence of complications, specifically hypertension, chronic renal insufficiency (CRI), urinary tract infection (UTI), and malignancy. Mean follow-up was 5 years. At approximately 1 year, 59% of unaffected kidneys were hypertrophied (≥95th percentile for age/ height) and 100% were >50th percentile. With continued follow-up, 80.3% of unaffected kidneys were hypertrophied. Likewise, at 1 year, 71.2% of MCDKs assessed were either involuting or had disappeared; on further follow-up, this increased to 89.6%. No patient had hypertension, CRI, or malignancy. Four patients (5%) developed nonrecurrent UTIs, none leading to renal scarring or growth impairment. These data suggest that subspecialty follow-up may be discontinued once contralateral hypertrophy and ipsilateral involution occur, assuming that the patient has not experienced hypertension, CRI, or UTI. These criteria are often met by 1 year of age, which would preclude repeated visits, uncomfortable investigations, and unnecessary costs.

KW - MCDK involution

KW - Multicystic dysplastic kidney (MCDK)

KW - Prognosis

KW - Simple MCDK

KW - Single kidney compensatory hypertrophy

KW - Treatment

KW - Unilateral cystic kidney

UR - http://www.scopus.com/inward/record.url?scp=37049001233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37049001233&partnerID=8YFLogxK

U2 - 10.1007/s00467-007-0635-7

DO - 10.1007/s00467-007-0635-7

M3 - Article

C2 - 17957387

AN - SCOPUS:37049001233

VL - 23

SP - 111

EP - 116

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 1

ER -